GlobeNewswire Clinical StudiesOriginal article
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Data ReadoutpositiveVerekitugPositive
AI Analysis
Summary
Upstream Bio presented Phase 2 VALIANT trial results showing verekitug 100 mg administered every 12 weeks reduced annualized asthma exacerbation rate by 56% compared to placebo in severe asthma patients. Results were presented in oral format at ERS Congress 2026.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Verekitug 100 mg dosed every 12 weeks reduced AAER by 56% compared to placebo in patients with severe asthma
Importance:6/10
Sentiment:
0.70
Phase 2AsthmaData ReadoutConference Presentation
Read the original article
Published by GlobeNewswire Clinical Studies on September 8, 2026 7:30 AM